secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001213900-25-001407
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology provides LYMPHIR launch update; commercialization planned for H1 2025
--------------------------------------------------------------------------------

- LYMPHIR (immunotherapy for CTCL) approved Aug 2024; launch targeted for first half of 2025.
- First-year launch supply produced under commercial supply agreements with CMOs.
- J-code application submitted under HCPCS; NCCN guidelines inclusion secured.
- Patient assistance program and specialized field sales team under development.
- Exploring international licensing partnerships and expanded indications for LYMPHIR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025001407/0001213900-25-001407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025001407/ea0226984-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-001407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer